AwardedPOLGoodsPLN 6,466,000
Dostawa substancji czynnej mirvetuximabum soravtansinum stosowanej w programie lekowym B.50 leczenia chorych na raka jajnika
- Published
- Published 28 May 2026
- Deadline
- Closed 12 June 2026
Overview
The University Clinical Hospital No. 2 in Szczecin procured the active substance mirvetuximabum soravtansinum for the pharmaceutical program B.50 treating ovarian cancer patients at its Department of Operative Gynecology and Gynecological Oncology. Abbvie Sp. z o.o was awarded the contract on 1 July 2026 for 6,299,996.4 PLN to supply the medicinal product over a 24-month period, with a minimum shelf life of 12 months from delivery and pricing not exceeding the established reimbursement limit.
Key details
- Country
- POL
- Status
- Awarded
- Category
- Goods
- Estimated value
- PLN 6,466,000
- Procedure
- Open
- SME suitable
- Yes
- Published
- 28 May 2026
- Deadline
- Closed
Antineoplastic agents
Award outcome
- Awarded value
- PLN 6,299,996
- Award date
- 1 July 2026
- Contract period
- — → 20 June 2028
- Abbvie Sp. z o.o
Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.
Notice history
Every published notice in this contracting process, newest first.
Contract Award Notice
13 July 2026
Contract Notice
28 May 2026
Contracting authority
UNIWERSYTECKI SZPITAL KLINICZNY NR 2 PUM W SZCZECINIE
Procuring entitySzczecin, POL
Authority website ↗
Get the full picture
AI analysis, bid scoring, and expert strategy for this tender
Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.
See which competitors are winning the contracts you're chasing.
15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.